The current first line treatment of a patient with mantle cell lymphoma (MCL) is often considered as too toxic for elderly patients. The elderly, however, comprise the majority of the patients with MCL. The results of several recent studies have shown that the outcome of this patient group is not as dismal as in the past. Indeed, if patients are not considered frail, and can tolerate rituximab and moderate intensive chemotherapy such as R-CHOP followed by rituximab maintenance or R-bendamustine, a 4-year overall survival of >80% can be achieved. In this chapter the developments of the regimens, resulting in the standard treatment options for these patients, are discussed.

Additional Metadata
Keywords Bendamustine, Bortezomib, Cytarabine, Elderly patients, Induction therapy, Lenalidomide, Maintenance therapy, Mantle cell lymphoma, R-CHOP, Toxicity
Persistent URL dx.doi.org/10.1016/j.beha.2017.07.006, hdl.handle.net/1765/111357
Journal Best Practice and Research in Clinical Haematology
Citation
Kluin-Nelemans, J.C. (Johanna C.), & Doorduijn, J.K. (2018). What is the optimal initial management of the older MCL patient?. Best Practice and Research in Clinical Haematology (Vol. 31, pp. 99–104). doi:10.1016/j.beha.2017.07.006